Transfer factor for adjuvant immunotherapy in cervical cancer

Area of Science:

• Oncology
• Immunology
• Gynecologic Oncology

Background:

• Invasive cervical cancer poses a significant health challenge.
• Understanding immune system roles in cancer recurrence is crucial for developing novel therapies.
• Transfer factor (TF) is a cell-derived immune modulator.

Purpose of the Study:

• To evaluate the efficacy of transfer factor (TF) therapy in preventing recurrence of invasive cervical cancer post-surgery.
• To assess the impact of TF on patient outcomes in different age groups and disease stages.

Main Methods:

• Prospective randomized double-blind study involving 60 patients with invasive cervical cancer.
• Patients were randomized to receive either transfer factor (TF) derived from leukocyte donors or a placebo.
• Recurrence rates were monitored for 2 years post-radical hysterectomy; immune profiles of donors and recipients were analyzed.

Main Results:

• A significantly lower rate of malignancy recurrence was observed in the TF-treated group (5/32) compared to the placebo group (11/28) within 2 years.
• This significant difference (P < 0.05) was particularly notable in patients under 35 years old and those with stage I disease.
• Antigen-specific immune reactivity correlations were found between donors and recipients, but not with the clinical course.

Conclusions:

• Transfer factor (TF) therapy may be a beneficial adjunct in reducing the risk of invasive cervical cancer recurrence after radical hysterectomy.
• The therapy appears more effective in younger patients and those with early-stage disease.
• Further research is warranted to elucidate the precise mechanisms and optimize TF application in gynecologic oncology.